Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Petros Pharmaceuticals Inc PTPI

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment... see more

Recent & Breaking News (NDAQ:PTPI)

Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology

GlobeNewswire April 26, 2022

Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil)

GlobeNewswire April 19, 2022

Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights

GlobeNewswire April 1, 2022

Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference

GlobeNewswire March 3, 2022

Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health

PR Newswire February 1, 2022

Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ (avanafil) to the United States

PR Newswire January 24, 2022

Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug STENDRA® (avanafil)

PR Newswire January 18, 2022

Petros Pharmaceuticals Announces Closing of $7.5 Million Offering

PR Newswire December 28, 2021

Petros Pharmaceuticals Announces $7.5 Million Offering

PR Newswire December 22, 2021

Petros Pharmaceuticals Announces Positive Over-the-Counter (OTC) Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA® (avanafil)

PR Newswire December 8, 2021

Petros Pharmaceuticals Announces Closing of $10 Million Offering

PR Newswire December 2, 2021

Petros Pharmaceuticals to Present at the Benzinga Global Small Cap Conference

PR Newswire December 2, 2021

Petros Pharmaceuticals Announces $10 Million Offering

PR Newswire November 30, 2021

Petros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

PR Newswire November 15, 2021

Petros Pharmaceuticals to Present at the Q4 Investor Summit Conference

PR Newswire November 11, 2021

Petros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease

PR Newswire November 8, 2021

Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. Generates 476% Year-Over-Year Growth of STENDRA Tablet Sales

PR Newswire November 3, 2021

Petros Pharmaceuticals to Participate at Upcoming Benzinga Conference and Interview Show

PR Newswire October 21, 2021

Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering

PR Newswire October 19, 2021

Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering

PR Newswire October 14, 2021